A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.

doi:10.1038/s41388-021-02003-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.

Oncogene - 1 Oct 2021

Di Giulio Stefano, Colicchia Valeria, Pastorino Fabio, Pedretti Flaminia, Fabretti Francesca, Nicolis di Robilant Vittoria, Ramponi Valentina, Scafetta Giorgia, Moretti Marta, Licursi Valerio, Belardinilli Francesca, Peruzzi Giovanna, Infante Paola, Goffredo Bianca Maria, Coppa Anna, Canettieri Gianluca, Bartolazzi Armando, Ponzoni Mirco, Giannini Giuseppe, Petroni Marialaura

Abstract excerpt

MYCN drives aggressive behavior and refractoriness to chemotherapy, in several tumors. Since MYCN inactivation in clinical settings is not achievable, alternative vulnerabilities of MYCN-driven tumors need to be explored to identify more effective and less toxic therapies. We previously demonstrated that PARP inhibitors enhance MYCN-induced replication stress and promote mitotic catastrophe, counteracted by CHK1....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cerebellar Neoplasms

Share to Drug Synergism

Share to Medulloblastoma

Share to N-Myc Proto-Oncogene Protein

Share to Neuroblastoma

Share to Phthalazines

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 34508175
DOI: 10.1038/s41388-021-02003-0
PMCID: PMC8553625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.PMID 34508175Read ↗

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma CellsSemantic proximity Read ↗

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.Semantic proximity Read ↗

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastomaSemantic proximity Read ↗

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastomaSemantic proximity Read ↗

Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell deathSemantic proximity Read ↗

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma CellsSemantic proximity Read ↗

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma CellsSemantic proximity Read ↗

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer CellsSemantic proximity Read ↗

Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.